The Impact of Surgery on the Survival of Patients with Recurrent Glioblastoma

Oumar Sacko; Alexandra Benouaich-Amiel; Pierre Brandicourt; Mahamadou Niaré; Saloua Charni; Clarissa Cavandoli; David Brauge; Isabelle Catalaa; Adam Brenner; Elizabeth Cohen-Jonathan Moyal; Franck-Emmanuel Roux

doi:10.4103/ajns.AJNS_180_20

The Impact of Surgery on the Survival of Patients with Recurrent Glioblastoma

Asian J Neurosurg. 2021 Feb 23;16(1):1-7. doi: 10.4103/ajns.AJNS_180_20. eCollection 2021 Jan-Mar.

Authors

Oumar Sacko^{1

2}, Alexandra Benouaich-Amiel^{1

2}, Pierre Brandicourt^{1

2}, Mahamadou Niaré^{1

2

3}, Saloua Charni^{1

2

3}, Clarissa Cavandoli^{1

2}, David Brauge^{1

2}, Isabelle Catalaa^{4

2}, Adam Brenner⁵, Elizabeth Cohen-Jonathan Moyal^{2

6}, Franck-Emmanuel Roux^{1

2

3}

Affiliations

¹ Pôle Neurosciences, Neurochirurgie, PPR, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France.
² Université Paul-Sabatier, Toulouse, France.
³ CNRS (Centre Recherche et Cognition), Toulouse, France.
⁴ Neuroradiologie, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France.
⁵ Western University of Health Sciences, Pomona, USA.
⁶ Harrison Medical Center, Bremerton, WA, USA.

Abstract

Objective: The purpose of this study was to investigate the possible benefit of repeat surgery on overall survival for patients with recurrent glioblastoma multiforme (GBM).

Methods: We performed a retrospective analysis of data from patients who presented with recurrent GBM over a 5-year period (n = 157), comparing baseline characteristics and survival for patients who had at least 1 new tumor resection followed by chemotherapy (reoperation group, n = 59) and those who received medical treatment only (no-reoperation group, n = 98) for recurrence.

Results: The baseline characteristics of the two groups differed in terms of WHO performance status (better in the reoperation group), mean age (60 years in the reoperation group vs. 65 years in the no-reoperation group), mean interval to recurrence (3 months later in the reoperation group than in the no-reoperation group) and more gross total resections in the reoperation group. Nevertheless, the patients in the reoperation group had a higher rate [32.8%] of sensorimotor deficits than those of the no-reoperation group [14.2]. There was no significant difference in sex; tumor localization, side, or extent; MGMT status; MIB-1 labeling index; or Karnofsky Performance Status [KPS] score. After adjustment for age, the WHO performance status, interval of recurrence, and extent of resection at the first operation, multivariate analysis showed that median survival was significantly better in the reoperation group than in the no-reoperation group (22.9 vs. 14.61 months, P < 0.05). After a total of 69 repeat operations in 59 patients (10 had 2 repeat surgeries), we noted 13 temporary and 20 permanent adverse postoperative events, yielding a permanent complication rate of 28.99% (20/69). There was also a statistically significant (P = 0.029, Student's t-test) decrease in the mean KPS score after reoperation (mean preoperative KPS score of 89.34 vs. mean postoperative score of 84.91).

Conclusion: Our retrospective study suggests that repeat surgery may be beneficial for patients with GBM recurrence who have good functional status (WHO performance status 0 and 1), although the potential benefits must be weighed against the risk of permanent complications, which occurred in almost 30% of the patients who underwent repeat resection in this series.

Keywords: Extent of resection; glioblastoma; neuro-oncology; recurrence; redo surgery; reoperation.